PhaseBio Pharmaceuticals Non-current Liabilities (Other)

Non-current Liabilities (Other) of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Non-current Liabilities (Other) growth rates and interactive chart.


Highlights and Quick Summary

  • Non-current Liabilities (Other) for the quarter ending September 29, 2021 was $94.8 Million (a 5.29% increase compared to previous quarter)
  • Year-over-year quarterly Non-current Liabilities (Other) increased by 81.31%
  • Annual Non-current Liabilities (Other) for 2020 was $52.3 Million (a 25652.71% increase from previous year)
  • Annual Non-current Liabilities (Other) for 2019 was $203 Thousand (a 822.73% increase from previous year)
  • Annual Non-current Liabilities (Other) for 2018 was $22 Thousand (a -98.68% decrease from previous year)
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Non-current Liabilities (Other) of PhaseBio Pharmaceuticals

Most recent Non-current Liabilities (Other)of PHAS including historical data for past 10 years.

Interactive Chart of Non-current Liabilities (Other) of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Non-current Liabilities (Other) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $94.78 $90.02 $68.89
2020 $52.28 $32.7 $15.07 $3.38 $52.28
2019 $0.2 $0.12 $0.06 $0.2
2018 $0.02
2017 $1.66
2016 $0.89

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.